Skip to main content
ASTRO 2024 Main banner
Icon Legend
Presentation Icons
Event Add-on
Event Add-on
In Person Only
In Person Only
Off-site Event
Off-site Event
Location: Marriott Marquis
Location: Marriott Marquis
Back

Jonathan Yang, MD, PhD

New York University School of Medicine
New York, NY

Dr. Jonathan Yang is an Associate Professor at New York University School of Medicine Department of Radiation Oncology. He serves as the Associate Vice Chair of Clinical Research and Developmental Therapeutics and the Director of Metastatic Disease Service in the Department. He is also the Director of Clinical Research for the Laura and Isaac Perlmutter Cancer Center-Brain and Spine Tumor Center. His clinical and academic expertise is in central nervous system malignancies, metastatic disease, and precision radiation oncology through rational combination of novel therapeutics with radiotherapy for which he serves as the principal investigator of several ongoing first-in-human trials investigating DNA damage response inhibitors with radiation. He is also focused on translational biomarker development to guide appropriate treatment selection in patients with metastatic cancers. In addition, combing his passions in central nervous system malignancies and metastatic disease Dr. Yang has a special focus in advancing the treatment of patients with leptomeningeal disease. He has run several practice changing studies in these areas and developed programs using novel therapeutic agents as radiation sensitizers in genetically stratified patient subsets with cancer that has metastasized to the CNS. Lastly, he has worked to develop biomarkers to drive therapeutic decision-making using CSF cell-free circulating tumor DNA and circulating tumor cells.

Disclosures:

  • Employment: New York University School of Medicine:Attending:Employee;University of Washington:Associate Professor:Employee
  • Compensation: AstraZeneca: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: 4/2022 ;Kazia Therapeutics: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: 10/2022 ;Nanocan Therapeutics: Advisory Board, Advisory Board Type, Advisory Board Proprietary-End Date: ongoing ;Galera Therapeutics: Consultant, Compensation Payment-End Date: ongoing ;AstraZeneca: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: ongoing ;Kazia Therapeutics: Research Grants, Research Funding, Research Salary Support, Grant Research Funding-End Date: ongoing ;Kazia Therapeutics: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Grant Research Funding, Compensation Payment-End Date: present ;Nanocan Therapeutics: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Compensation Payment-End Date: present ;Plus Therapeutics: Consultant, Compensation Payment-End Date: prese
  • Ownership: none
  • Leadership: none

Presentation(s):